Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918720 | 0.78 | ALDH1A1 (0.46) | KDM4ETSHRMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL917325 | 0.74 | KDM4E (0.40) | KDM4ETSHRMCL1MEN1KMT2A | |
| SCHEMBL3314489 | 0.71 | SIGMAR1 (0.46) | POLB | |
| SCHEMBL20874462 | 0.71 | SIGMAR1 (0.49) | — | |
| SCHEMBL27723716 | 0.68 | SIGMAR1 (0.46) | KDM4ETSHRMCL1SMN1; SMN2 | |
| SCHEMBL7868181 | 0.67 | CCR3 (0.51) | — | |
| SCHEMBL13597026 | 0.67 | OPRL1 (0.47) | SLC6A2SLC6A4MEN1KMT2ACHRM2 | |
| SCHEMBL918210 | 0.66 | HTR2A (0.36) | MEN1KMT2A | |
| Water SCHEMBL3313361 | 0.64 | KMT2A (0.43) | KDM4EMEN1KMT2ASMN1; SMN2EPHX2 | |
| SCHEMBL5540150 | 0.64 | KDM4E (0.54) | KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BHI LIMITED PARTNERSHIP (CA) | 2014-04-17 | — | — | US | disclosed |
| US-8642801-B2 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2014-02-04 | — | — | US | disclosed |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2010-05-06 | — | — | US | disclosed |
| US-7414076-B2 | Methods and compositions for treating amyloid-related diseases | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-08-19 | — | — | US | disclosed |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1644325-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | Neurochem (International) Limited (CH) | 2006-04-12 | — | — | EP | disclosed |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | BHI LIMITED PARTNERSHIP (CA) | 2005-05-05 | — | — | US | disclosed |
| WO-2004113275-A2 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107027-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SLC6A2 790/4885SLC6A4 2439/4885KDM4E 4713/4885 |
| US-20100113591-A1 | METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | SLC6A2 790/4885SLC6A4 2439/4885KDM4E 4713/4885 |
| US-20050096385-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SLC6A2 790/4885SLC6A4 2439/4885KDM4E 4713/4885 |
| US-20070010573-A1 | Methods and compositions for treating amyloid-related diseases | APP, PSEN1, PSEN2 | SLC6A2 790/4885SLC6A4 2439/4885KDM4E 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.